Virtu KCG Holdings’s United Therapeutics UTHR Stock Holding History

Virtu KCG Holdings’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,174	Closed	-$836K	–	3531
2017 Q1	$836K	Sell	6,174 -1,782	-22%	-$270K	0.02%	859
2016 Q4	$1.14M	Buy	+7,956	New	+$1.02M	0.03%	654
2016 Q2	–	Sell	-4,579	Closed	-$510K	–	3361
2016 Q1	$510K	Buy	4,579 +2,020	+79%	+$256K	0.01%	1168
2015 Q4	$401K	Sell	2,559 -3,819	-60%	-$556K	0.01%	1804
2015 Q3	$837K	Buy	6,378 +4,245	+199%	+$681K	0.01%	1034
2015 Q2	$371K	Buy	+2,133	New	+$384K	0.01%	1797
2015 Q1	–	Sell	-5,143	Closed	-$666K	–	3908
2014 Q4	$666K	Buy	5,143 +941	+22%	+$121K	0.01%	1349
2014 Q3	$541K	Buy	+4,202	New	+$433K	0.01%	1613
2014 Q1	–	Sell	-3,919	Closed	-$443K	–	4102
2013 Q4	$443K	Buy	+3,919	New	+$353K	﹤0.01%	2106

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu KCG Holdings's UTHR Position: Q2 2017 in Review

Virtu KCG Holdings sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 6,174 shares — an estimated $836K sold.

Virtu KCG Holdings first reported a position in UTHR in Q4 2013 and held it in 9 quarters. The position peaked at $1.14M in Q4 2016. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

Virtu KCG Holdings reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 6,174 United Therapeutics shares in Q2 2017, an estimated $836K.
Virtu KCG Holdings first reported a position in United Therapeutics in Q4 2013 and held it in 9 quarters.
Virtu KCG Holdings's United Therapeutics position peaked at $1.14M in Q4 2016.
373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.